DD120103A1 - - Google Patents

Info

Publication number
DD120103A1
DD120103A1 DD18714375A DD18714375A DD120103A1 DD 120103 A1 DD120103 A1 DD 120103A1 DD 18714375 A DD18714375 A DD 18714375A DD 18714375 A DD18714375 A DD 18714375A DD 120103 A1 DD120103 A1 DD 120103A1
Authority
DD
German Democratic Republic
Application number
DD18714375A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to DD18714375A priority Critical patent/DD120103A1/xx
Publication of DD120103A1 publication Critical patent/DD120103A1/xx

Links

DD18714375A 1975-07-07 1975-07-07 DD120103A1 (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DD18714375A DD120103A1 (enExample) 1975-07-07 1975-07-07

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD18714375A DD120103A1 (enExample) 1975-07-07 1975-07-07

Publications (1)

Publication Number Publication Date
DD120103A1 true DD120103A1 (enExample) 1976-05-20

Family

ID=5500965

Family Applications (1)

Application Number Title Priority Date Filing Date
DD18714375A DD120103A1 (enExample) 1975-07-07 1975-07-07

Country Status (1)

Country Link
DD (1) DD120103A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021218895A1 (zh) 2020-04-29 2021-11-04 正大天晴药业集团股份有限公司 针对PD-1和TGF-β的双功能蛋白
WO2023046037A1 (zh) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
WO2024193516A1 (zh) 2023-03-17 2024-09-26 百奥泰生物制药股份有限公司 抗ox40抗体在治疗炎症或免疫性疾病中的应用
WO2025044937A1 (zh) 2023-08-31 2025-03-06 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021218895A1 (zh) 2020-04-29 2021-11-04 正大天晴药业集团股份有限公司 针对PD-1和TGF-β的双功能蛋白
WO2023046037A1 (zh) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
WO2024193516A1 (zh) 2023-03-17 2024-09-26 百奥泰生物制药股份有限公司 抗ox40抗体在治疗炎症或免疫性疾病中的应用
EP4681731A1 (en) 2023-03-17 2026-01-21 Bio-Thera Solutions, Ltd. Use of anti-ox40 antibody in treatment of inflammations or immune diseases
WO2025044937A1 (zh) 2023-08-31 2025-03-06 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用

Similar Documents

Publication Publication Date Title
JPS5268933U (enExample)
JPS5249532U (enExample)
BG21685A1 (enExample)
BG22141A1 (enExample)
BG22167A1 (enExample)
BG22187A1 (enExample)
BG22298A1 (enExample)
BG22546A1 (enExample)
BG22572A1 (enExample)
BG22630A1 (enExample)
BG22900A1 (enExample)
BG23124A1 (enExample)
BG23278A1 (enExample)
CH1426175A4 (enExample)
CH583534A5 (enExample)
CH584087A5 (enExample)
CH585089A5 (enExample)
CH588707A5 (enExample)
CH588727B5 (enExample)
CH589366A5 (enExample)
CH590401A5 (enExample)
CH591640A5 (enExample)
CH591715A5 (enExample)
CH591799A5 (enExample)
CH592262A5 (enExample)